Clinical Trial

InRAD Observational Study

Study acronym: InRAD
Recruiting
View on ClinicalTrials.gov →
Summary
The goal of this international observational study is to evaluate long-term disease outcomes and treatment safety in people with Alzheimer's disease (PwAD), by collecting real-world data from routine clinical practice across global clinical centers. The InRAD Registry Observational Study has several aims: * To collect medical information for many years from a large group of people with Alzheimer's disease. This will be used for research, which will support improved understanding about the disease. * To enable researchers to look at the effectiveness, usefulness and safety of treatments for Alzheimer's disease. * To enable researchers to answer similar research questions and compare results in many different areas of the world. People with Alzheimer's disease who meet the eligibility criteria and agree to participate in the Study will be asked to visit their doctor (e.g. psychiatrist, geriatrician, or neurologist) at least once a year, or as frequently as is needed for their care. During or after their appointments they may be offered assessments, tests, medications, and treatments as determined by their doctor and their team. This is an observational data collection.
Protocol Amendment History 2 changes
notable Trial sites expanded: 7 -> 11 locations 2026-08-14
notable Trial sites expanded: 2 -> 6 locations 2026-06-30
Trial Details
NCT Number NCT07213700
Lead Sponsor Stichting International Registry for Alzheimer's Disease and other Dementias Foundation
Collaborators: InRAD Foundation (Data Processor), Principal Investigator
Conditions Alzheimer's Disease(AD), Mild Cognitive Impairment (MCI), Subjective Cognitive Decline (SCD), Non-Alzheimer Degenerative Dementia
Enrollment 50,000 participants
Start Date 2026-03-30
Primary Completion 2036-01 (estimated)
Study Completion 2036-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-13